EMEA-001796-PIP03-16-M02
Key facts
| Invented name |
Calquence
|
| Active substance |
Acalabrutinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0408/2021
|
| PIP number |
EMEA-001796-PIP03-16-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
ACERTA PHARMA, BV
Tel. +31 412700 576 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|